Abstract P187: Aortic Arch Width is Associated with Increasing Age and Cardiovascular Disease Risk Factors: The Framingham Heart Study
Introduction: Aortic arch geometry changes with aging: curvature decreases and aortic arch width (AAW) increases. AAW can be easily measured using thoracic multidetector computed tomography (MDCT). In addition to greater age, increases in AAW may also occur due to other cardiovascular disease (CVD) risk factors, but the distribution and determinants of excess AAW are unknown. We hypothesized that, in addition to increasing age, standard CVD risk factors are associated with increased AAW in community-dwelling adults.
Methods: 3026 (1560 men) Offspring and Third Generation cohort participants (men ≥35y; women ≥40y) underwent thoracic MDCT (2002-2005) and had complete risk factor profiles. AAW was defined as the distance between centroids of the ascending and descending aorta at the level of main pulmonary artery bifurcation. A healthy referent group free of CVD, hypertension, dyslipidemia, smoking, and diabetes was used to generate sex and 10-year age group specific upper 90th percentile (P90) cutpoints for AAW. Multivariable-adjusted, step-wise logistic regression was used to determine associations between high (≥referent P90) AAW and candidate risk factors in the overall study group.
Results: 1471 participants (738 M) met referent group criteria: AAW was greater in men than women (p<0.0001). In each sex, AAW increased substantially with greater age-group (p for trend <0.0001 both). Mean (±SD) and P90 AAW values are shown in the Table. In the entire study population, high AAW was associated with body mass index (OR=1.12; 95% confidence interval 1.10-1.14), diastolic BP (OR=1.46/10mmHg; 1.26-1.70), log pack-years (OR=1.09; 1.03-1.14), and prevalent CVD (OR=1.82; 1.21-2.74) in multivariable models.
Conclusions: AAW increases with greater age, obesity, diastolic blood pressure, and cigarette smoking in both men and women. High AAW is also associated with prevalent CVD. These findings lay the groundwork for assessment of the potential clinical utility of AAW.
Author Disclosures: S. Qazi: None. P. Gona: None. R.M. Musgrave: None. C.S. Fox: None. J.M. Massaro: None. U. Hoffmann: None. M.L. Chuang: None. C.J. O'Donnell: None.
- © 2015 by American Heart Association, Inc.